"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 5 | 5 |
| 2006 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 4 | 6 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 6 | 6 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
?c cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1. Cytotherapy. 2022 Dec; 24(12):1232-1244.
-
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.
-
An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer. Biosensors (Basel). 2021 Jan 03; 11(1).
-
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
-
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol. 2020 Oct; 14(10):1007-1011.
-
Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020 Apr; 21(6):653-661.
-
Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles. J Mater Chem B. 2020 02 21; 8(7):1411-1421.
-
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
-
Essential role of TNF-a in gamma c cytokine aided crosstalk between dendritic cells and natural killer cells in experimental murine lymphoma. Int Immunopharmacol. 2020 Jan; 78:106031.
-
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.